However, profound preclinical and clinical data are required to safely conclude that CD38 targeting via nanobody-based CAR-Ts does not mediate off-tumor cytotoxicity against T cells, B cells, and NK cells proficient in the expression of CD38. The gene discussed is CD38; the disease is neoplasm.